{"classes":[{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the time from the start of the treatment-free remission (TFR) phase to the earliest occurrence of disease progression to accelerated phase (AP) or blast crisis (BC), or death due to any cause. Participants without an event on or before the data cut-off date were censored at the date of their last available disease assessment (cytogenetic, hematologic, or extramedullary assessment) or last contact for participants in follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who completed the nilotinib treatment consolidation (NTCS) phase and maintained major molecular response entered the treatment-free remission (TFR) phase. During the TFR phase, nilotinib treatment was discontinued and participants were monitored regularly for molecular response.","id":"OG000","title":"TFR Phase"}],"paramType":"MEDIAN","populationDescription":"The full analysis set (FAS) included all participants who completed 52 weeks of nilotinib treatment in the NTCS phase and subsequently entered the treatment-free remission (TFR) phase.","reportingStatus":"POSTED","timeFrame":"From start of the treatment-free remission (TFR) phase up to Week 528","title":"Progression-Free Survival (PFS) After Start of the Treatment-Free Remission (TFR) Phase","type":"SECONDARY","unitOfMeasure":"Weeks"}